At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NKTX Nkarta
Not Yet Opened 11-14 16:00:00 EST
2.70
-0.21
-7.22%
盘后2.71
+0.01+0.37%
19:46 EST
High2.93
Low2.62
Vol1.09M
Open2.90
D1 Closing2.91
Amplitude10.65%
Mkt Cap190.54M
Tradable Cap109.61M
Total Shares70.57M
T/O3.00M
T/O Rate2.68%
Tradable Shares40.60M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Nkarta to Participate in an Upcoming Investor Conference
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.